1,364 reports of this reaction
3.2% of all ALIROCUMAB reports
#2 most reported adverse reaction
PRODUCT DOSE OMISSION is the #2 most commonly reported adverse reaction for ALIROCUMAB, manufactured by Regeneron Pharmaceuticals, Inc.. There are 1,364 FDA adverse event reports linking ALIROCUMAB to PRODUCT DOSE OMISSION. This represents approximately 3.2% of all 42,209 adverse event reports for this drug.
Patients taking ALIROCUMAB who experience product dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION is moderately reported among ALIROCUMAB users, representing a notable but not dominant share of adverse events.
In addition to product dose omission, the following adverse reactions have been reported for ALIROCUMAB:
The following drugs have also been linked to product dose omission in FDA adverse event reports:
PRODUCT DOSE OMISSION has been reported as an adverse event in 1,364 FDA reports for ALIROCUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION accounts for approximately 3.2% of all adverse event reports for ALIROCUMAB, making it one of the most commonly reported side effect.
If you experience product dose omission while taking ALIROCUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.